Analysts Offer Insights on Healthcare Companies: Bellerophon Therapeutics LLC (NASDAQ: BLPH), MyoKardia Inc. (NASDAQ: MYOK) and BeiGene, Ltd. (NASDAQ: BGNE)

By George MacDonald

There’s a lot to be optimistic about in the Healthcare sector as 2 experts just weighed in on Bellerophon Therapeutics LLC (NASDAQ: BLPH), MyoKardia Inc. (NASDAQ: MYOK) and BeiGene, Ltd. (NASDAQ: BGNE) with bullish sentiments.

Bellerophon Therapeutics LLC (NASDAQ: BLPH)

In a report released yesterday, Ritu Baral from Cowen & Co. reiterated a Buy rating on Bellerophon (NASDAQ: BLPH), with a price target of $12. The company’s shares opened today at $1.53, close to its 52-week low of $1.09.

Baral said, “BLPH reported Q2 financials yesterday.”

According to TipRanks.com, Baral is a 4-star analyst with an average return of 4.4% and a 43.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on Bellerophon is Moderate Buy and the average price target is $12, representing a 684.3% upside.

In a report issued on August 9, FBR Capital also reiterated a Buy rating on the stock.
MyoKardia Inc. (NASDAQ: MYOK)

In a report released yesterday, Ritu Baral from Cowen & Co. reiterated a Buy rating on MyoKardia Inc (NASDAQ: MYOK), with a price target of $24. The company’s shares opened today at $18.60, close to its 52-week high of $20.

Baral noted, “MYOK Ph1/2 MYK-461 data shows key biomarker improvements in 2 patients with.”

According to TipRanks.com, Baral is a 4-star analyst with an average return of 4.4% and a 43.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

MyoKardia Inc has an analyst consensus of Strong Buy, with a price target consensus of $24

.
BeiGene, Ltd. (NASDAQ: BGNE)

Cowen & Co. analyst Eric Schmidt reiterated a Buy rating on BeiGene, Ltd (NASDAQ: BGNE) yesterday. The company’s shares opened today at $27.50.

Schmidt noted, “BeiGene reported a Q2 net loss of $24MM and ended the quarter with a cash balance.”

According to TipRanks.com, Schmidt is a top 100 analyst with an average return of 22.2% and a 55.0% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

BeiGene, Ltd has an analyst consensus of Moderate Buy

.